A month has gone by since the last earnings report for Charles River Laboratories (CRL) . Shares have added about 6.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Charles River due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Charles River Q4 Earnings Beat, Mar ...

Charles River Laboratories International, Inc. (CRL) inked an AAV9 production program deal with Navega Therapeutics. The deal will grant Navega Therapeutics access to Charles River’s contract development and manufacturing capabilities and advisory services to produce the AAV gene therapy candidate NT-Z001 for phase 1 clinical trials.The recent move will bolster Charles River’s Biologics Solutions.More on the NewsUsing the accuracy of its AI-enabled zinc finger epigenome regulatory technology, Navega Therape ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z0 ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver. ...

Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time.However, there are still bargains to be found… outside of the technology sector. With these three top healthcare stocks to buy, for example, there are high quality companies still selling at affordable prices. If and when the market enthusiasm spreads into the healthcare sector, these three stocks should surge.Johnson & Johnson (JNJ)Source: Alexander Tolstykh / Shutterstock.comJohns ...

WILMINGTON, Mass. and OKLAHOMA CITY, Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreement with Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in pharma services, to offer Wheeler Bio's Portable CMC® (Chemistry, Manufacturing and Controls) platform to Charles River Laboratory clients. The collaboration is designed to enable a swift transition from pre-clinical stages directl ...

Charles River Laboratories International, Inc. (CRL) recently announced a strategic partnership with Wheeler Bio, an antibody CDMO (contract development and manufacturing organization) focused on the pre-clinical and early clinical supply of recombinant proteins, providing clients with access to Wheeler’s Portable CMC (Chemistry, Manufacturing and Controls) platform. The new alliance provides early-stage biotechnology companies with a unique solution to rapidly transition from pre-clinical activities to fir ...

Charles River Laboratories (CRL) continues to gain from the CRADL initiative. However, the competitive landscape is a concern. The stock carries a Zacks Rank #3 (Hold) currently.Research Models and Services (RMS) business services are in high demand among Charles River’s clients in the field of basic research and screening of non-clinical drug candidates. The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. Through most of 2023, the company witnes ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2023 Results Conference Call February 14, 2024 8:30 AM ET Company Participants Todd Spencer - Vice President of Investor Relations James Foster - President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Derek De Bruin - Bank of America Patrick Donnelly - Citigroup Elizabeth Anderson - Evercore ISI David Windley - Jefferies LLC Justin Bowers - Deutsche Bank Jacob Johnson ...